Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Amag Pharmaceuticals Inc's Business Segments
Amag Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 93
Regions Reported
-
Amag Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product78.7%
- Feraheme50.2%
- Makena27.8%
- License and Service21.3%
- Product, Other0.7%
- Product and Service, Other0%
- Intrarosa0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 73 | 78.7% |
| Feraheme | $ 47 | 50.2% |
| Makena | $ 26 | 27.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
4 more categories available
Sign in to unlock the full Amag Pharmaceuticals Inc dataset.
Description of Amag Pharmaceuticals Inc
Amag Pharmaceuticals Inc. is a publicly-traded biopharmaceutical company headquartered in Waltham, Massachusetts. It was founded in 1981 and is focused on developing innovative therapies to improve patients' lives.
Amag Pharmaceuticals Inc. has a diverse product portfolio that includes drugs for the treatment of various medical conditions. The company's core therapeutic areas are women's health, anemia, and cancer supportive care.
One of Amag's flagship products is Makena, a hormone injection used to prevent preterm birth in women who have a history of preterm birth. The company acquired the rights to Makena from Hologic in 2014, and it has been a significant contributor to Amag's revenue since then.
The company also has two FDA-approved drugs, Feraheme and MuGard, that are used to treat iron deficiency anemia and the oral mucositis associated with chemotherapy and radiation, respectively.
In addition to its marketed products, Amag Pharmaceuticals is also engaged in research and development of new medicines. The company has a robust pipeline that comprises several promising drugs at various stages of development.
AMAG-423, for example, is an investigational therapy that is being evaluated for the treatment of severe preeclampsia, a potentially life-threatening pregnancy complication. Another compound, Vyleesi, is a self-administered injection that is being developed to address hypoactive sexual desire disorder in women.
The company's research and development efforts also include exploring the potential of the synthetic lactoferrin protein to treat iron deficiency anemia, as well as innovative technologies for drug delivery and formulation.
Overall, Amag Pharmaceuticals Inc. is a research-driven pharmaceutical company that is committed to developing innovative therapies for significant, unmet medical needs. The company's key strengths lie in women's health, anemia, and cancer supportive care, and it leverages its expertise in these areas to drive innovation and value for patients and investors alike.
Amag Pharmaceuticals Inc. has a diverse product portfolio that includes drugs for the treatment of various medical conditions. The company's core therapeutic areas are women's health, anemia, and cancer supportive care.
One of Amag's flagship products is Makena, a hormone injection used to prevent preterm birth in women who have a history of preterm birth. The company acquired the rights to Makena from Hologic in 2014, and it has been a significant contributor to Amag's revenue since then.
The company also has two FDA-approved drugs, Feraheme and MuGard, that are used to treat iron deficiency anemia and the oral mucositis associated with chemotherapy and radiation, respectively.
In addition to its marketed products, Amag Pharmaceuticals is also engaged in research and development of new medicines. The company has a robust pipeline that comprises several promising drugs at various stages of development.
AMAG-423, for example, is an investigational therapy that is being evaluated for the treatment of severe preeclampsia, a potentially life-threatening pregnancy complication. Another compound, Vyleesi, is a self-administered injection that is being developed to address hypoactive sexual desire disorder in women.
The company's research and development efforts also include exploring the potential of the synthetic lactoferrin protein to treat iron deficiency anemia, as well as innovative technologies for drug delivery and formulation.
Overall, Amag Pharmaceuticals Inc. is a research-driven pharmaceutical company that is committed to developing innovative therapies for significant, unmet medical needs. The company's key strengths lie in women's health, anemia, and cancer supportive care, and it leverages its expertise in these areas to drive innovation and value for patients and investors alike.
Amag Pharmaceuticals Inc. is a biopharmaceutical company dedicated to addressing unmet medical needs through the research, development, and commercialization of innovative therapies. The companys offerings can be categorized into distinct segments, products, and services, all aimed at improving patient care in specific therapeutic areas.
Segments
1. Feraheme Segment:
- Feraheme represents Amags commitment to addressing iron deficiency anemia (IDA) particularly in adult patients with chronic kidney disease (CKD). This segment focuses not only on the marketing and distribution of Feraheme but also on ongoing research to further understand its capabilities and potential applications.
2. Intrarosa Segment:
- This segment revolves around the development and commercialization of Intrarosa, targeting women suffering from moderate to severe dyspareunia—often resulting from menopause. By focusing on localized hormone replacement therapy, the segment seeks to enhance the quality of life for postmenopausal women through efficacious treatment options.
3. Vyleesi Segment:
- The Vyleesi segment addresses the needs of premenopausal women dealing with hypoactive sexual desire disorder (HSDD). This segments efforts emphasize the promotion of awareness and education regarding womens sexual health, as well as the therapeutic benefits of Vyleesi.
Products
1. Feraheme:
- Feraheme (ferumoxytol) is an innovative intravenous iron replacement therapy utilized to treat IDA in adult patients with CKD. The product is specifically formulated as a colloidal iron hydroxide complex, allowing for effective and rapid replenishment of iron stores, which can significantly improve hemoglobin levels. Feraheme is particularly advantageous for patients who cannot tolerate oral iron supplements or those who have non-dialysis-dependent forms of CKD.
2. Intrarosa:
- Intrarosa (dehydroepiandrosterone, or DHEA) is a locally applied hormone therapy designed for postmenopausal women experiencing dyspareunia. As a DHEA prodrug, it undergoes metabolism in the body to produce endogenous androgens and estrogens, which play a crucial role in restoring vaginal health and alleviating discomfort during intercourse. The once-daily dosing regimen is designed to enhance patient compliance and comfort.
3. Vyleesi:
- Vyleesi (bremelanotide) is a melanocortin receptor agonist delivered via subcutaneous injection. It is indicated for premenopausal women suffering from acquired, generalized HSDD. By activating specific receptors in the brain associated with sexual desire, Vyleesi represents a novel treatment approach, providing women with a proactive solution to enhance their sexual health and overall well-being.
Services
1. Patient Access Services:
- Amag Pharmaceuticals is dedicated to ensuring that patients can access its products through comprehensive patient access services. This includes reimbursement assistance, financial assistance programs, and co-pay assistance plans designed to reduce the financial burden on patients and facilitate their treatment journey.
2. Medical Affairs:
- The medical affairs department at Amag provides critical scientific and medical information to healthcare professionals and patients alike. This service ensures that stakeholders are well-informed about the products, their therapeutic benefits, and any emerging data resulting from ongoing clinical research.
3. Clinical Development:
- The clinical development division is pivotal to Amags strategy for innovation. This department is responsible for designing and conducting rigorous clinical trials aimed at evaluating the safety and efficacy of new and existing products. By investing in thorough research and development processes, Amag Pharmaceuticals prioritizes the approval and success of therapies that meet stringent regulatory standards and truly address the needs of the patient population.
In summary, Amag Pharmaceuticals Inc. operates with a clear focus on delivering specialized therapies for iron deficiency anemia and womens sexual health issues. Through its innovative segments, targeted products, and robust support services, the company is committed to improving patient outcomes and responding to specific medical challenges.
Segments
1. Feraheme Segment:
- Feraheme represents Amags commitment to addressing iron deficiency anemia (IDA) particularly in adult patients with chronic kidney disease (CKD). This segment focuses not only on the marketing and distribution of Feraheme but also on ongoing research to further understand its capabilities and potential applications.
2. Intrarosa Segment:
- This segment revolves around the development and commercialization of Intrarosa, targeting women suffering from moderate to severe dyspareunia—often resulting from menopause. By focusing on localized hormone replacement therapy, the segment seeks to enhance the quality of life for postmenopausal women through efficacious treatment options.
3. Vyleesi Segment:
- The Vyleesi segment addresses the needs of premenopausal women dealing with hypoactive sexual desire disorder (HSDD). This segments efforts emphasize the promotion of awareness and education regarding womens sexual health, as well as the therapeutic benefits of Vyleesi.
Products
1. Feraheme:
- Feraheme (ferumoxytol) is an innovative intravenous iron replacement therapy utilized to treat IDA in adult patients with CKD. The product is specifically formulated as a colloidal iron hydroxide complex, allowing for effective and rapid replenishment of iron stores, which can significantly improve hemoglobin levels. Feraheme is particularly advantageous for patients who cannot tolerate oral iron supplements or those who have non-dialysis-dependent forms of CKD.
2. Intrarosa:
- Intrarosa (dehydroepiandrosterone, or DHEA) is a locally applied hormone therapy designed for postmenopausal women experiencing dyspareunia. As a DHEA prodrug, it undergoes metabolism in the body to produce endogenous androgens and estrogens, which play a crucial role in restoring vaginal health and alleviating discomfort during intercourse. The once-daily dosing regimen is designed to enhance patient compliance and comfort.
3. Vyleesi:
- Vyleesi (bremelanotide) is a melanocortin receptor agonist delivered via subcutaneous injection. It is indicated for premenopausal women suffering from acquired, generalized HSDD. By activating specific receptors in the brain associated with sexual desire, Vyleesi represents a novel treatment approach, providing women with a proactive solution to enhance their sexual health and overall well-being.
Services
1. Patient Access Services:
- Amag Pharmaceuticals is dedicated to ensuring that patients can access its products through comprehensive patient access services. This includes reimbursement assistance, financial assistance programs, and co-pay assistance plans designed to reduce the financial burden on patients and facilitate their treatment journey.
2. Medical Affairs:
- The medical affairs department at Amag provides critical scientific and medical information to healthcare professionals and patients alike. This service ensures that stakeholders are well-informed about the products, their therapeutic benefits, and any emerging data resulting from ongoing clinical research.
3. Clinical Development:
- The clinical development division is pivotal to Amags strategy for innovation. This department is responsible for designing and conducting rigorous clinical trials aimed at evaluating the safety and efficacy of new and existing products. By investing in thorough research and development processes, Amag Pharmaceuticals prioritizes the approval and success of therapies that meet stringent regulatory standards and truly address the needs of the patient population.
In summary, Amag Pharmaceuticals Inc. operates with a clear focus on delivering specialized therapies for iron deficiency anemia and womens sexual health issues. Through its innovative segments, targeted products, and robust support services, the company is committed to improving patient outcomes and responding to specific medical challenges.